Carl Stefan Fraenkel
Directeur/Membre du Conseil chez Akinion Pharmaceuticals AB
Profil
Carl Stefan Fraenkel is currently a Director at Akinion Pharmaceuticals AB.
Previously, he worked as Vice President & Head-Business Development at Swedish Orphan Biovitrum AB from 2011 to 2012.
He holds an MBA and a doctorate from Copenhagen Business School, and an undergraduate degree from Chalmers University of Technology.
Postes actifs de Carl Stefan Fraenkel
| Sociétés | Poste | Début |
|---|---|---|
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | - |
Anciens postes connus de Carl Stefan Fraenkel
| Sociétés | Poste | Fin |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Formation de Carl Stefan Fraenkel
| Copenhagen Business School | Doctorate Degree |
| Chalmers University of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
